Pasadena Institutes of Medical Research study shows men taking erectile dysfunction drugs have lower rates of heart failure – Pasadena Now


According to a study conducted by scientists from the Huntington Medical Research Institutes (HMRI) in Pasadena, HealthCore Inc. and the University of California, San Francisco.

The study was presented at American Heart Association scientific meetings in Reston, Va., on Friday, May 13.

Scientists analyzed the health records of more than 70,000 men with erectile dysfunction and compared rates of major adverse cardiovascular events (MACE) like strokes and deaths among men who took PDE-5i drugs (phosphodiesterase type 5 inhibitor) – including Viagra, Cialis and Levitra – at rates in men who have never taken these drugs.

“We initially viewed this study as a study of cardiovascular safety, but were surprised to see the association between the use of these medications and significant beneficial effects on cardiovascular outcomes,” said Dr. Robert A. Kloner, Scientific Director and Scientific Director. of cardiovascular research at HMRI, Pasadena said. “These drugs may have cardioprotective effects that could possibly go beyond their current uses.”

Dr. Kloner is the principal investigator of the study.

“Our research represents the first time that the effect of PDE-5i drugs on cardiovascular health has been explored in a large population of relatively low-risk men with erectile dysfunction in the United States,” said Dr. Julia E. Bradsher, President and CEO of HMRI. and the team’s co-investigator, added. “The number of patients involved gives us great confidence in the results.”

Among men who took PDE-5i drugs for erectile dysfunction, Kloner’s study identified a 39% reduction in death from heart disease, a 22% reduction in unstable angina, a reduction in 17% reduction in heart failure, a 15% reduction in the need for revascularization procedures such as angioplasty, stenting and bypass surgery; a 13% reduction in major adverse cardiovascular events (MACE) and a 25% reduction in all-cause deaths.

The study also found that men who received more than one PDE-5i drug had greater reductions in MACE, including a 55% reduction among those with the highest number of pills dispensed compared to those who had the least.

Kloner and his co-investigators extracted anonymized patient records from a large database of commercial insurance and Medicare claims in the United States. The study, funded by a grant from Sanofi, looked at records over about 14 years.

Other study team members include Eric Stanek, Christopher L. Crowe, Mukul Singhal, and Rebecca S. Pepe of Healthcore Inc., and Raymond Rosen of the University of California, San Francisco.

Kloner said more research is needed to prove that PDE-5i drugs caused the observed reduction in cardiovascular events. But if PDE-5i drugs are found to cause these effects, he said they could provide new therapies that would help prevent a number of adverse cardiovascular conditions, including heart failure and stroke-related deaths. coronary diseases.

“Another focus of our research is investigating new therapies to reduce heart attack size or reduce heart failure after a heart attack,” Kloner said. “Such therapies have the potential to save thousands of lives.”

Get our daily Pasadena newspaper delivered to your inbox. Free.

Get all the latest Pasadena news, 10+ new stories a day, 7 days a week at 7 a.m.


Comments are closed.